New clinical trial for ASPS is expected to open on March 2016.
This is a phase II clinical trial that combines treatment with Axitinib and Pembrolizumab in patients with advanced Alveolar Soft Part Sarcoma (ASPS) and other soft tissue sarcomas.
Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor.
Pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda) is an antibody used in cancer immunotherapy to target the programmed cell death 1 (PD-1) receptor.
Patients will be treated with twice daily dosing of axitinib alone for the first 7 days, followed by concurrent axitinib administered twice daily at 5 mg orally (PO), plus intravenous administration of pembrolizumab every 21 days. Patients will be assessed every three weeks for toxicity.
The study will include up to 30 patients
Breelyn Wilky, MD, University of Miami
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)